2310001H12Rik Inhibitors
Chemical inhibitors of 2310001H12Rik function by disrupting specific signaling pathways that are essential for its activity. Wortmannin and LY294002 are both inhibitors of phosphatidylinositol 3-kinases (PI3Ks), a family of enzymes involved in cellular functions such as growth, proliferation, differentiation, motility, and survival. The inhibition of PI3Ks by these chemicals leads to a reduction in AKT kinase activation, a downstream target of PI3K. Since the activity of 2310001H12Rik may be dependent on AKT signaling, its functional activity can be inhibited by Wortmannin and LY294002. Similarly, PD98059 and U0126 target the MAPK/ERK pathway by selectively inhibiting MEK1 and MEK2. This inhibition prevents the activation of extracellular signal-regulated kinases (ERK), which may be necessary for 2310001H12Rik function. Consequently, the activity of 2310001H12Rik can be blocked by these inhibitors.
SB203580 and SP600125 inhibit the p38 MAP kinase and c-Jun N-terminal kinase (JNK) pathways, respectively. SB203580's specificity for p38 MAP kinase means that it can reduce signaling through this particular pathway, leading to a decrease in downstream effects that might be required for 2310001H12Rik to function. On the other hand, SP600125 inhibits JNK, which may affect the activity of 2310001H12Rik if it is reliant on JNK signaling. Other inhibitors like Dasatinib, Sorafenib, and Sunitinib act on various receptor tyrosine kinases and other kinases such as Src family kinases, ABL1, VEGFR, PDGFR, and Raf kinases. By inhibiting these kinases, these chemicals disrupt the signaling pathways that could be critical for the proper function of 2310001H12Rik. Rapamycin, targeting the mTOR pathway, leads to decreased signaling that could be vital for 2310001H12Rik activity. Erlotinib and Imatinib, which inhibit EGFR and Bcr-Abl tyrosine kinase respectively, can also lead to the inhibition of 2310001H12Rik if it is activated by signals propagated through these kinases.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits phosphatidylinositol 3-kinases (PI3Ks), which are involved in various signaling pathways. Inhibition of PI3Ks can lead to decreased AKT activation, and if 2310001H12Rik is downstream of AKT, this would result in its inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, functioning similarly to Wortmannin. By hindering PI3K activity, LY294002 can reduce AKT signaling. The inhibition of AKT can lead to the functional inhibition of 2310001H12Rik if AKT signaling is necessary for its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinases (ERK). Blocking this pathway can inhibit 2310001H12Rik if its activity relies on ERK signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a highly selective inhibitor of both MEK1 and MEK2, which affects the MAPK/ERK pathway. The disruption of this pathway can lead to the inhibition of 2310001H12Rik by preventing necessary phosphorylation events. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase. Inhibition of p38 MAPK can lead to decreased downstream signaling, which can functionally inhibit 2310001H12Rik if it is dependent on p38 MAPK activation for its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which impacts the JNK signaling pathway. If 2310001H12Rik requires JNK pathway activation for its function, inhibition by SP600125 would result in its functional inhibition. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib inhibits Src family kinases and the tyrosine-protein kinase ABL1. Inhibition of these kinases can disrupt various signaling pathways, including those that might involve 2310001H12Rik, leading to its inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an inhibitor of the mammalian target of rapamycin (mTOR) pathway. Inhibition of mTOR can affect downstream signaling that may be crucial for the function of 2310001H12Rik, leading to its inhibition. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple receptor tyrosine kinases, such as VEGFR, PDGFR, and Raf kinases. Inhibition of these kinases can disrupt signaling required for 2310001H12Rik activity, leading to its functional inhibition. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is an inhibitor of receptor tyrosine kinases including PDGFR and VEGFR. By inhibiting these kinases, Sunitinib can impair signaling pathways that are essential for the function of 2310001H12Rik, leading to its inhibition. | ||||||